U.K. Erectile Dysfunction Market – Industry Trends and Forecast to 2031

U.K. Erectile Dysfunction Market, By Product Type (Drugs and Devices), Type (Secondary Erectile Dysfunction and Primary Erectile Dysfunction), Age Group (Less than 40, 40-60 and 60 - Above), End User (Hospital, Specialty Clinics, Home Healthcare, Ambulatory Surgical Centers and Others), Distribution Channel (Direct Tenders, Retail Pharmacy, Online Pharmacy, Hospital Pharmacy and Others) - Industry Trends and Forecast to 2031.

U.K. Erectile Dysfunction Market Analysis and Insights

Rising rates of ED condition among men and changing lifestyles & environmental factors impacting health are some of the drivers boosting the demand in the market. The government initiatives to improve this condition and wellbeing is further propelling the market growth.

The major restraint which is impacting the market is the adverse effects associated with certain products. The increasing chronic diseases and lifestyle is acting as an opportunity for the market growth. Less availability of skilled professional is acting as challenge for the market growth.

Data Bridge Market Research analyzes that the U.K. erectile dysfunction market is expected to reach USD 451.63 million by 2031 from USD 260.49 million thousand in 2023, growing with a CAGR of 7.2% in the forecast period of 2024 to 2031.

Market Definition

Erectile Dysfunction (ED) is the inability to get or keep an erection firm enough to have sexual intercourse. It’s sometimes referred to as “impotence,” but this term is now used less often. Erectile dysfunction is an ongoing issue, that can cause stress, affect your self-confidence and contribute to relationship

ED can occur because of problems at any stage of the erection process, and it can be occasional or frequent:

• Occasional ED isn’t uncommon. Many people experience it during times of stress or as the result of a recent nutritional or lifestyle change.
• Frequent ED, however, can be a sign of health problems that need treatment. It can also be a symptom of emotional or relationship difficulties that you may want to address with a professional.

You get an erection when blood fills two chambers known as the corpora cavernosa. This causes your penis to expand and stiffen, much like a balloon as it is filled with water. Impulses from the brain and genital nerves start the process. Anything that blocks these impulses or restricts blood flow to the penis can cause ED.

U.K. Erectile Dysfunction Market Dynamics

This section deals with understanding the market drivers, opportunities, restraints, and challenges. All of this is discussed in detail below:     

Driver

• Rising Prevalence of Chronic Diseases

Diabetes can lead to damage to blood vessels throughout the body, a condition known as diabetic vasculopathy. This vascular damage can impair blood flow to various organs, including the penis, leading to erectile dysfunction. Over time, the cumulative effects of diabetes-related vascular damage increase the likelihood of erectile dysfunction (ED) occurrence and severity. Diabetes often causes neuropathy, a condition characterized by nerve damage. Peripheral neuropathy affects the nerves outside the brain and spinal cord, including those that control erection and sexual arousal. As a result, diabetic neuropathy can disrupt the normal neurological pathways involved in achieving and maintaining an erection, contributing to ED.

Restraint

• Regulatory Constraints for Approval

In the United Kingdom, the regulatory constraints in the erectile dysfunction (ED) market primarily revolve around the approval and marketing of medications and treatments for ED. The MHRA (Medicines and Healthcare products Regulatory Agency) is the U.K regulatory agency responsible for ensuring the safety, quality, and efficacy of medicines and medical devices. Any medication intended for the treatment of ED must undergo rigorous evaluation and approval by the MHRA before it can be marketed and prescribed in the U.K. Many medications used to treat ED, such as sildenafil (Viagra), tadalafil (Cialis), and vardenafil (Levitra), are classified as POMs (Prescription-Only Medicine) in the UK. This means they can only be obtained with a prescription from a qualified healthcare professional, such as a doctor or a pharmacist prescriber.

To gain regulatory approval, pharmaceutical companies must conduct extensive clinical trials to demonstrate the safety and efficacy of their ED medications. The MHRA evaluates these trial data to determine whether the benefits of the medication outweigh any potential risks.

Opportunity

• Availability of Prescription Medication and its Generic Version

The availability of prescription medications for ED ensures that individuals have access to effective treatment options. Prescription medications such as sildenafil (generic Viagra), tadalafil (generic Cialis), and vardenafil (generic Levitra) are proven to be effective in treating ED by improving blood flow to the penis. By making these medications readily available through healthcare providers, individuals with ED can seek timely treatment, leading to improved quality of life and satisfaction.

Generic versions of prescription medications for ED are typically priced lower than their branded counterparts. This increased affordability makes treatment more accessible to a wider population, including those who may have been previously unable to afford branded medications. As a result, more individuals are likely to seek treatment for ED, driving demand in the market.

Challenge

• Various Side Effects Associated with Erectile Dysfunction Drugs

Side effects associated with ED drugs, such as headache, flushing, dizziness, nasal congestion, and gastrointestinal discomfort, raise concerns about patient safety and tolerability. These adverse reactions may deter some individuals from using ED medications or lead to discontinuation of treatment, resulting in reduced market demand and slower growth.

Side effects can affect patient compliance with ED medication regimens. Individuals may be less likely to adhere to prescribed dosing schedules or may discontinue treatment altogether if they experience bothersome side effects. Poor treatment compliance can compromise treatment outcomes and reduce the effectiveness of ED drugs, hindering market growth by limiting the number of individuals benefiting from therapy.

Recent Developments

• In November 2023, Rigicon, Inc. published a comprehensive study highlights Rigi10TM Malleable Penile Prosthesis safety outcomes implanted worldwide. The clinical study, titled “Safety Outcomes of the First Rigi10 Malleable Penile Prostheses Implanted Worldwide” provides a comprehensive evaluation of the safety of the Rigi10 Malleable Penile Prosthesis. This study underscores the device’s status as a reliable solution for patients seeking treatment for Erectile Dysfunction (ED). This has helped the company to strengthen its product portfolio for treating erectile dysfunction.
• In April 2021, as per NCBI, Zephyr Surgical Implants modified the pump-cylinders connection tube of ZSI 475 developing an additional reinforcement that should provide more sturdiness to the prosthesis. This has helped the company to strengthen its product portfolio.

U.K. Erectile Dysfunction Market Scope

The U.K. erectile dysfunction market is segmented into twelve notable segments based on product, route of administration, dosage, product type, mode of purchase, type, population type, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the differences in your target markets.

By Product Type

• Drugs
• Devices

By Type

• Secondary Erectile Dysfunction
• Primary Erectile Dysfunction

By Age Group

• Less than 40
• 40-60
• 60 - Above

By End User

• Hospital
• Specialty Clinics
• Home Healthcare
• Ambulatory Surgical Centers
• Others

By Distribution Channel

• Direct Tender
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

U.K. Erectile Dysfunction Market Share Analysis and Competitive Landscape

The U.K. erectile dysfunction market competitive landscape provides details of competitors. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product approvals, product width and breadth, application dominance, and product type lifeline curve. The above data points provided are only related to the company’s focus on the market.

Some of the major market players operating in the market are Lupin, Teva Pharmaceutical Industries Ltd., Augusta Medical Systems, Boston Scientific Corporation, Coloplast Corp, Rigicon, Inc., Pfizer Inc., Bayer AG, Eli Lily and Company, Viatris Inc., ZSI, Zephyr Surgical Implants and among others.